<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400759</article-id><article-id pub-id-type="pmc">PMC12092644</article-id><article-id pub-id-type="doi">10.3389/fonc.2025.1603501</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Correction</subject></subj-group></subj-group></article-categories><title-group><article-title>Corrigendum: Lipid have a direct effect on multiple myeloma: a Mendelian randomization study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Yingbin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanhao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Weipeng</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xiao</surname><given-names>Mingfeng</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2695466/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Guangdong Clinical Research Academy of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>First Clinical Medical College, Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>College of Traditional Chinese Medicine, Jinan University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited and Reviewed by: Alessandro Isidori, AORMN Hospital, Italy</p></fn><corresp id="fn001">*Correspondence: Mingfeng Xiao, <email xlink:href="mailto:xiaomingfeng2022@163.com">xiaomingfeng2022@163.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>06</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>15</volume><elocation-id>1603501</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhong, Li, Sun and Xiao</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhong, Li, Sun and Xiao</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" id="RA1" xlink:href="10.3389/fonc.2024.1404744" journal-id="Front Oncol" journal-id-type="nlm-ta">A Corrigendum on <article-title>Lipid have a direct effect on multiple myeloma: a Mendelian randomization study</article-title> By Zhong Y, Li Y, Sun W and Xiao M (2024). <italic>Front. Oncol.</italic> 14:1404744. doi:&#x000a0;<object-id>10.3389/fonc.2024.1404744</object-id>
</related-article><kwd-group><kwd>multiple myeloma</kwd><kwd>lipid</kwd><kwd>single nucleotide polymorphisms</kwd><kwd>Mendelian randomization</kwd><kwd>genome&#x02010;wide association study</kwd><kwd>causal relationship</kwd></kwd-group><counts><fig-count count="6"/><table-count count="1"/><equation-count count="0"/><ref-count count="0"/><page-count count="6"/><word-count count="953"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Hematologic Malignancies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>In the published article, there was an error in the article title. Instead of &#x0201c;Liposomes have a direct effect on multiple myeloma: A Mendelian randomization study&#x0201d;, it should be &#x0201c;Lipid have a direct effect on multiple myeloma: A Mendelian randomization study&#x0201d;.</p><p>In the published article, there was an error in the legend for <xref rid="f2" ref-type="fig">
<bold>Figures&#x000a0;2</bold>
</xref>&#x02013;<xref rid="f7" ref-type="fig">
<bold>7</bold>
</xref>, <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> as published. The term &#x0201c;liposomes&#x0201d; is commonly associated with lipid-based drug delivery systems. In our study, we used it to describe the lipid profile in plasma and its potential impact on disease mechanisms, which may cause confusion. The corrected legends appear below.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>A flow-chart of MR study to explore the causal relationship between lipid and multiple myeloma.</p></caption><graphic xlink:href="fonc-15-1603501-g002" position="float"/></fig><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>The effect of various lipid on multiple myeloma.</p></caption><graphic xlink:href="fonc-15-1603501-g003" position="float"/></fig><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>The causal effect of six plasma lipid on MM risk; GCST90277317: Phosphatidylcholine (18:2_20:4) levels; GCST90277247: Sterol ester (27:1/18:3) levels; GCST90277344: Phosphatidylcholine (O-18:2_20:4); GCST90277348: Phosphatidylethanolamine (18:0_20:4); GCST90277358: Phosphatidylinositol (16:0_18:1) levels; GCST90277410: Triacylglycerol (56:4) levels.</p></caption><graphic xlink:href="fonc-15-1603501-g004" position="float"/></fig><fig position="float" id="f5"><label>Figure&#x000a0;5</label><caption><p>The funnel plot of the causal effect of six plasma lipid on MM risk. It&#x02019;s almost symmetrical on both sides, which indicated no significant heterogeneity between the effect estimates of the IVs in both the IVW method and MR-Egger method.</p></caption><graphic xlink:href="fonc-15-1603501-g005" position="float"/></fig><fig position="float" id="f6"><label>Figure&#x000a0;6</label><caption><p>Leave-one-out analysis of the causal association between six lipid and MM. The exclusion of individual SNPs did not result in substantial differences in the combined effect estimates between the remaining SNPs and the overall results.</p></caption><graphic xlink:href="fonc-15-1603501-g006" position="float"/></fig><fig position="float" id="f7"><label>Figure&#x000a0;7</label><caption><p>The reverse MR analysis of MM on six plasma lipid.</p></caption><graphic xlink:href="fonc-15-1603501-g007" position="float"/></fig><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Results of multiplicity and sensitivity analyses of six lipid.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" rowspan="2" align="left" colspan="1">Description<break/>Lipid</th><th valign="middle" colspan="2" align="left" rowspan="1">MR-Egger</th><th valign="middle" colspan="2" align="left" rowspan="1">MR-heterogeneity</th><th valign="middle" colspan="2" align="left" rowspan="1">MR-pleiotropy</th><th valign="middle" colspan="2" align="left" rowspan="1">MR-PRESSO_Global</th><th valign="middle" rowspan="2" align="left" colspan="1">Power</th></tr><tr><th valign="middle" align="left" rowspan="1" colspan="1">OR(95%Cl)</th><th valign="middle" align="left" rowspan="1" colspan="1">p-value</th><th valign="middle" align="left" rowspan="1" colspan="1">Cochran&#x02019;s Q</th><th valign="middle" align="left" rowspan="1" colspan="1">p-value</th><th valign="middle" align="left" rowspan="1" colspan="1">intercept</th><th valign="middle" align="left" rowspan="1" colspan="1">p-value</th><th valign="middle" align="left" rowspan="1" colspan="1">RSS</th><th valign="middle" align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Phosphatidylethanolamine (18:0_20:4)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.48 (0.22-1.03)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.08</td><td valign="middle" align="left" rowspan="1" colspan="1">13</td><td valign="middle" align="left" rowspan="1" colspan="1">0.978</td><td valign="middle" align="left" rowspan="1" colspan="1">0.055</td><td valign="middle" align="left" rowspan="1" colspan="1">0.345</td><td valign="middle" align="left" rowspan="1" colspan="1">5.740</td><td valign="middle" align="left" rowspan="1" colspan="1">0.96</td><td valign="middle" align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Phosphatidylcholine (18:2_20:4)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.89 (0.44-1.82)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.76</td><td valign="middle" align="left" rowspan="1" colspan="1">21</td><td valign="middle" align="left" rowspan="1" colspan="1">0.985</td><td valign="middle" align="left" rowspan="1" colspan="1">-0.035</td><td valign="middle" align="left" rowspan="1" colspan="1">0.435</td><td valign="middle" align="left" rowspan="1" colspan="1">10.350</td><td valign="middle" align="left" rowspan="1" colspan="1">0.97</td><td valign="middle" align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Phosphatidylinositol (16:0_18:1)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.69 (0.32-1.46)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.35</td><td valign="middle" align="left" rowspan="1" colspan="1">13</td><td valign="middle" align="left" rowspan="1" colspan="1">0.897</td><td valign="middle" align="left" rowspan="1" colspan="1">0.005</td><td valign="middle" align="left" rowspan="1" colspan="1">0.932</td><td valign="middle" align="left" rowspan="1" colspan="1">8.073</td><td valign="middle" align="left" rowspan="1" colspan="1">0.89</td><td valign="middle" align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Sterol ester (27:1/18:3)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.73 (0.46-1.18)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.22</td><td valign="middle" align="left" rowspan="1" colspan="1">15</td><td valign="middle" align="left" rowspan="1" colspan="1">0.974</td><td valign="middle" align="left" rowspan="1" colspan="1">0.008</td><td valign="middle" align="left" rowspan="1" colspan="1">0.897</td><td valign="middle" align="left" rowspan="1" colspan="1">6.789</td><td valign="middle" align="left" rowspan="1" colspan="1">0.98</td><td valign="middle" align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Triacylglycerol (56:4)</td><td valign="middle" align="left" rowspan="1" colspan="1">2.12 (0.65-6.88)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.26</td><td valign="middle" align="left" rowspan="1" colspan="1">7</td><td valign="middle" align="left" rowspan="1" colspan="1">0.571</td><td valign="middle" align="left" rowspan="1" colspan="1">-0.025</td><td valign="middle" align="left" rowspan="1" colspan="1">0.755</td><td valign="middle" align="left" rowspan="1" colspan="1">7.464</td><td valign="middle" align="left" rowspan="1" colspan="1">0.60</td><td valign="middle" align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Phosphatidylcholine (O&#x02212;18:2_20:4)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.83 (0.29-2.34)</td><td valign="middle" align="left" rowspan="1" colspan="1">0.73</td><td valign="middle" align="left" rowspan="1" colspan="1">12</td><td valign="middle" align="left" rowspan="1" colspan="1">0.802</td><td valign="middle" align="left" rowspan="1" colspan="1">0.073</td><td valign="middle" align="left" rowspan="1" colspan="1">0.312</td><td valign="middle" align="left" rowspan="1" colspan="1">9.457</td><td valign="middle" align="left" rowspan="1" colspan="1">0.77</td><td valign="middle" align="left" rowspan="1" colspan="1">0.91</td></tr></tbody></table></table-wrap><p>&#x0201c;Figure&#x000a0;2&#x000a0;A flow-chart of MR study to explore the causal relationship between lipid and multiple myeloma.&#x0201d;</p><p>&#x0201c;Figure&#x000a0;3 The effect of various lipid on multiple myeloma.&#x0201d;</p><p>&#x0201c;Figure&#x000a0;4 The causal effect of six plasma lipid on MM risk; GCST90277317: Phosphatidylcholine (18:2_20:4) levels; GCST90277247: Sterol ester (27:1/18:3) levels;&#x000a0;GCST90277344: Phosphatidylcholine (O-18:2_20:4); GCST90277348: Phosphatidylethanolamine (18:0_20:4); GCST90277358: Phosphatidylinositol (16:0_18:1) levels; GCST90277410: Triacylglycerol (56:4) levels.&#x0201d;</p><p>&#x0201c;Figure&#x000a0;5 The funnel plot of the causal effect of six plasma lipid on MM risk. It&#x02019;s almost symmetrical on both sides, which indicated no significant heterogeneity between the effect estimates of the IVs in both the IVW method and MR-Egger method.&#x0201d;</p><p>&#x0201c;Figure&#x000a0;6 Leave-one-out analysis of the causal association between six lipid and MM.&#x0201d;</p><p>&#x0201c;Figure&#x000a0;7 The reverse MR analysis of MM on six plasma lipid.&#x0201d;</p><p>&#x0201c;<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> Results of multiplicity and sensitivity analyses of six lipid&#x0201d;.</p><p>In the published article, there was an error in <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> as published. The term &#x0201c;liposomes&#x0201d; is commonly associated with lipid-based drug delivery systems. In our study, we used it to describe the lipid profile in plasma and its potential impact on disease mechanisms, which may cause confusion. Therefore, we changed &#x0201c;Liposome&#x0201d; to &#x0201c;Lipid&#x0201d;. The corrected <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> and its caption appear below.</p><p>In the published article, the reference for 7-11 which discuss &#x0201c;liposomes&#x0201d; was fully relevant to &#x0201c;lipid&#x0201d; It should be removed.</p><p>In the published article, there was an error. The term &#x0201c;liposomes&#x0201d; is commonly associated with lipid-based drug delivery systems. In our study, we used it to describe the lipid profile in plasma and its potential impact on disease mechanisms.</p><p>A correction has been made to <bold>Abstract, Introduction, Materials and methods, Results, Discussion, Conclusion</bold>, page 01-09. This word previously stated:</p><p>&#x0201c;liposomes&#x0201d;</p><p>The corrected sentence appears below:</p><p>&#x0201c;lipid&#x0201d;</p><p>A correction has been made to <bold>Introduction</bold>. This sentence previously stated:</p><p>&#x0201c;Liposomes, artificial bimolecular membranes composed primarily of phospholipids and cholesterol, are endogenous substances inherent to living organisms. Their compatibility with biological tissues and non-immunogenic nature makes them an ideal medium for drug delivery. As a nanoscale drug delivery system, liposomes have garnered interest for their capacity to encapsulate drugs effectively, optimizing their distribution within the body, enhancing targeting precision, and minimizing toxic side effects. In the realm of MM therapy, liposome technology emerges as a promising avenue for developing targeted therapeutic strategies aimed at enhancing treatment efficacy while reducing drug-induced toxicity (10, 11). Recent investigations suggest a significant role for specific human serum liposome components in MM pathogenesis.&#x0201d;</p><p>The corrected sentence appears below:</p><p>&#x0201c;Recent investigations suggest a significant role for specific human serum lipid components in MM pathogenesis.&#x0201d;</p><p>The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.</p></body><back><sec sec-type="disclaimer" id="s1"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></back></article>